Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | EBP | Q15125 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7535570 | 0.77 | SLC2A1 (0.54) | SLC2A1ALDH1A1TSHRALOX15HSD17B10 | |
| SCHEMBL8445728 | 0.76 | CCR1 (0.43) | TSHRHSD17B10MAPK1MEN1KMT2A | |
| SCHEMBL307300 | 0.76 | KIF11 (0.48) | ALDH1A1TSHRHSD17B10 | |
| SCHEMBL994398 | 0.76 | MAPT (0.43) | ALDH1A1TSHRHSD17B10MAPTMAPK1 | |
| SCHEMBL1141384 | 0.76 | CA1 (0.34) | ALDH1A1HSD17B10KMT2A | |
| SCHEMBL10389822 | 0.76 | ESR1 (0.54) | TSHRHSD17B10CYP3A4 | |
| SCHEMBL13271382 | 0.75 | CYP2D6 (0.44) | ALDH1A1TSHRCYP3A4RAB9AEBP | |
| SCHEMBL1756296 | 0.74 | CASP1 (0.34) | HSD17B10EBPSIGMAR1 | |
| SCHEMBL9786745 | 0.72 | USP2 (0.35) | HSD17B10KDM4EMAPK1RAB9AEBP | |
| SCHEMBL13272036 | 0.71 | SLC2A1 (0.52) | SLC2A1ALDH1A1TSHRALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162160-A1 | SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL)METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO | MILLENDO THERAPEUTICS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20200255372-A1 | SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL)METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO | MILLENDO THERAPEUTICS INC (US) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162160-A1 | SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL)METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO | ATR, BAP1, ATRIP | SLC2A1 4192/4885ALDH1A1 1452/4885TSHR 775/4885 |
| US-20200255372-A1 | SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL)METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO | ATR, BAP1, ATRIP | SLC2A1 4192/4885ALDH1A1 1452/4885TSHR 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.